Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options - Director/PDMR Shareholding

14 Dec 2022 17:08

RNS Number : 7510J
Evgen Pharma PLC
14 December 2022
 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 

PDMR

Position

Current Ordinary Shares held

Current Options held

New options granted

% of issued share capital including this award

Dr Huw Jones

CEO

62,500

4,648,890

4,410,727

3.3%

Richard Moulson

CFO

45,454

889,728

1,460,855

 

0.9%

 

The Options will vest on the third anniversary of grant based on performance against challenging

strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).

 

Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.

 

Enquiries:

Evgen Pharma plcDr Huw Jones, CEO Richard Moulson, CFO 

+44 1625 466591

FinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)Alice Lane/Nigel Birks (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon

+44 207 457 2020Evgen@Instinctif.co

 

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Huw Jones

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

4410727

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

CFO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

1460855

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUSRBRUSUUAAA
Date   Source Headline
22nd Mar 20217:00 amRNSAppointment of Chief Business Officer
15th Mar 20219:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSUpdate on Data Safety Review - STAR COVID-19 trial
9th Mar 202111:35 amRNSHolding(s) in Company
8th Mar 20211:49 pmRNSHolding(s) in Company
5th Mar 20214:04 pmRNSHolding(s) in Company
5th Mar 20219:17 amRNSDirector dealing
3rd Mar 202112:10 pmRNSResult of General Meeting & Total Voting Rights
3rd Mar 20217:00 amRNSResult of Open Offer
26th Feb 20214:39 pmRNSHolding(s) in Company
17th Feb 20219:58 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSUpdate on patient recruitment
12th Feb 20217:00 amRNSPosting of Circular & Notice of GM
2nd Feb 20213:15 pmRNSPlacing and Open Offer to raise up to £11 million
22nd Jan 20217:00 amRNSPreclinical data on a new therapeutic target
21st Jan 20217:00 amRNSPositive pre-clinical data for lead asset SFX-01
19th Jan 20217:00 amRNSPatient recruitment update in STAR-COVID 19 trial
23rd Dec 20202:05 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:00 pmRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSHalf-year Report
27th Nov 20202:33 pmRNSHolding(s) in Company
27th Nov 20209:15 amRNSHolding(s) in Company
23rd Nov 20207:00 amRNSRecruitment of first patient in STAR trial
11th Nov 20207:00 amRNSComment on the COVID-19 vaccine announcement
6th Nov 20209:25 amRNSHolding(s) in Company
29th Oct 202011:55 amRNSHolding(s) in Company
29th Oct 20209:09 amRNSHolding(s) in Company
26th Oct 20203:00 pmRNSHolding(s) in Company
23rd Oct 20207:00 amRNSAll approvals received for STAR trial to commence
6th Oct 20207:00 amRNSGrant of options
24th Sep 20207:00 amRNSAppointment of Chief Executive Officer
15th Sep 20207:00 amRNSLicence agreement with Juvenescence
18th Aug 20203:30 pmRNSHolding(s) in Company
18th Aug 20203:25 pmRNSHolding(s) in Company
14th Aug 20204:41 pmRNSSecond Price Monitoring Extn
14th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20203:40 pmRNSHolding(s) in Company
24th Jul 20209:47 amRNSShare option exercise and issue of equity
17th Jul 202012:05 pmRNSHolding(s) in Company
17th Jul 202012:02 pmRNSHolding(s) in Company
16th Jul 20202:52 pmRNSResult of AGM
7th Jul 202011:13 amRNSShare option exercise and issue of equity
6th Jul 20207:00 amRNSShare option exercise and issue of equity
23rd Jun 202011:44 amRNSHolding(s) in Company
23rd Jun 202011:38 amRNSHolding(s) in Company
19th Jun 20207:00 amRNSNotice of AGM
17th Jun 20209:38 amRNSHolding(s) in Company
17th Jun 20209:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.